We are a biopharmaceutical company focused on the development and commercialization of RP-323, a targeted gene repair, immunotherapy, and stem cell activator for treating neurological diseases, blood disorders, and such inflammatory disorders as ARDS (Adult Respiratory Distress Syndrome).
PhorMed is developing RP-323, a proprietary ‘platform’ technology, that has the ability to target multiple cell lines, repairing a broad range of cell types, benefiting the company with a healthy IP portfolio and the potential for multiple income streams.
RP-323 treats diseases upstream where issues start. It has the ability to add a needed phosphate to a pathway, turning the switch on/off inside the DNA, allowing proper DNA transcription and protein expression.
After multiple clinical studies RP-323 has been found to be safe and the company is now prepared to enter into the next phase of clinical trials advancing its pipeline in collaboration with two clinical sites in Atlanta Georgia.
